安潔科技(002635.SZ):擬向子公司安潔無線增資1860萬元
格隆匯11月23日丨安潔科技(002635.SZ)公佈,為進一步增強公司控股子公司安潔無線科技(蘇州)有限公司(“安潔無線”)在項目研發、市場拓展、項目定點、產品量產等方面的綜合實力,推動新能源汽車無線充電系統產品的產業化,安潔無線根據業務發展需求擬進行增資,由安潔科技、蘇州共建共榮管理諮詢合夥企業(有限合夥)(“共建共榮”)共同對安潔無線進行增資2100.4728萬元,將安潔無線的實繳資本由7899.5272萬元增加至1億元。
其中,安潔科技實繳資本增加1860.0047萬元,共建共榮實繳資本增加240.4681萬元,宋磊、陳衞東、梁明作為安潔無線的股東放棄本次增資的優先認購權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.